[ad_1]
Pharmaceuticals company Divis Laboratories on Friday reported a 26% rise in its consolidated net profit at ₹702 crore as compared to ₹557 crore in the same quarter last year. Meanwhile, its revenue from operations rose about 15% to ₹2,254 crore from ₹1,960.6 crore year-on-year (YoY).
Divi’s Labs forex gain in Q1 FY23 rose to ₹56 crore as against the gain of ₹20 crore in Q1 FY22. It witnessed a rise in tax expense at ₹149 crore from ₹257 crore (YoY).
Shares of Divis Labs were trading about 3% lower on the BSE at ₹3,820 apiece on the BSE in Friday’s afternoon deals. The pharma stock is down about 18% in 2022 (YTD) so far.
Download The Mint News App to get Daily Market Updates & Live Business News.
[ad_2]
Source link